Free Trial

Cytokinetics (CYTK) Competitors

Cytokinetics logo
$44.55 -2.02 (-4.34%)
Closing price 04:00 PM Eastern
Extended Trading
$45.42 +0.87 (+1.95%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CYTK vs. TEVA, SMMT, ITCI, GMAB, MRNA, VTRS, RDY, ASND, SRPT, and PCVX

Should you be buying Cytokinetics stock or one of its competitors? The main competitors of Cytokinetics include Teva Pharmaceutical Industries (TEVA), Summit Therapeutics (SMMT), Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Moderna (MRNA), Viatris (VTRS), Dr. Reddy's Laboratories (RDY), Ascendis Pharma A/S (ASND), Sarepta Therapeutics (SRPT), and Vaxcyte (PCVX). These companies are all part of the "pharmaceutical products" industry.

Cytokinetics vs.

Cytokinetics (NASDAQ:CYTK) and Teva Pharmaceutical Industries (NYSE:TEVA) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, community ranking, media sentiment and analyst recommendations.

Cytokinetics has higher earnings, but lower revenue than Teva Pharmaceutical Industries. Teva Pharmaceutical Industries is trading at a lower price-to-earnings ratio than Cytokinetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cytokinetics$18.47M285.55-$526.24M-$5.26-8.47
Teva Pharmaceutical Industries$16.54B1.08-$1.64B-$1.45-10.83

Cytokinetics has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Teva Pharmaceutical Industries has a beta of 0.82, meaning that its stock price is 18% less volatile than the S&P 500.

Cytokinetics presently has a consensus price target of $82.00, indicating a potential upside of 84.06%. Teva Pharmaceutical Industries has a consensus price target of $23.43, indicating a potential upside of 49.13%. Given Cytokinetics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cytokinetics is more favorable than Teva Pharmaceutical Industries.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytokinetics
0 Sell rating(s)
2 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.94
Teva Pharmaceutical Industries
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

Teva Pharmaceutical Industries received 516 more outperform votes than Cytokinetics when rated by MarketBeat users. However, 79.86% of users gave Cytokinetics an outperform vote while only 67.87% of users gave Teva Pharmaceutical Industries an outperform vote.

CompanyUnderperformOutperform
CytokineticsOutperform Votes
817
79.86%
Underperform Votes
206
20.14%
Teva Pharmaceutical IndustriesOutperform Votes
1333
67.87%
Underperform Votes
631
32.13%

54.0% of Teva Pharmaceutical Industries shares are held by institutional investors. 3.4% of Cytokinetics shares are held by company insiders. Comparatively, 0.6% of Teva Pharmaceutical Industries shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Teva Pharmaceutical Industries had 14 more articles in the media than Cytokinetics. MarketBeat recorded 24 mentions for Teva Pharmaceutical Industries and 10 mentions for Cytokinetics. Teva Pharmaceutical Industries' average media sentiment score of 0.73 beat Cytokinetics' score of 0.54 indicating that Teva Pharmaceutical Industries is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Cytokinetics
5 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teva Pharmaceutical Industries
13 Very Positive mention(s)
0 Positive mention(s)
11 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Teva Pharmaceutical Industries has a net margin of -9.91% compared to Cytokinetics' net margin of -17,906.25%. Teva Pharmaceutical Industries' return on equity of 42.46% beat Cytokinetics' return on equity.

Company Net Margins Return on Equity Return on Assets
Cytokinetics-17,906.25% N/A -50.21%
Teva Pharmaceutical Industries -9.91%42.46%6.65%

Summary

Cytokinetics beats Teva Pharmaceutical Industries on 10 of the 19 factors compared between the two stocks.

Remove Ads
Get Cytokinetics News Delivered to You Automatically

Sign up to receive the latest news and ratings for CYTK and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CYTK vs. The Competition

MetricCytokineticsPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$5.28B$6.99B$5.68B$8.32B
Dividend YieldN/A2.72%4.55%4.02%
P/E Ratio-8.287.2324.5519.25
Price / Sales285.55230.77395.7294.09
Price / CashN/A65.6738.1634.64
Price / Book-11.316.617.064.46
Net Income-$526.24M$142.13M$3.19B$247.07M
7 Day Performance2.93%2.79%1.49%3.05%
1 Month Performance-4.50%2.70%5.87%-2.85%
1 Year Performance-35.18%-4.42%14.94%4.63%

Cytokinetics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CYTK
Cytokinetics
4.3591 of 5 stars
$44.55
-4.3%
$82.00
+84.1%
-30.9%$5.28B$18.47M-8.28250
TEVA
Teva Pharmaceutical Industries
2.605 of 5 stars
$16.74
+2.5%
$23.43
+40.0%
+16.5%$18.97B$16.54B-11.5436,800
SMMT
Summit Therapeutics
2.3689 of 5 stars
$20.13
-3.2%
$34.11
+69.5%
+513.9%$14.85B$700,000.00-71.89110
ITCI
Intra-Cellular Therapies
3.6015 of 5 stars
$131.45
+0.1%
$106.08
-19.3%
+90.8%$13.98B$680.50M-151.09560Positive News
GMAB
Genmab A/S
4.1611 of 5 stars
$20.80
+1.4%
$41.33
+98.7%
-35.5%$13.76B$21.53B11.952,204
MRNA
Moderna
4.102 of 5 stars
$34.71
+0.3%
$59.60
+71.7%
-67.6%$13.39B$3.20B-3.743,900
VTRS
Viatris
1.9798 of 5 stars
$9.25
+1.6%
$10.50
+13.5%
-21.5%$11.04B$14.74B-12.5037,000
RDY
Dr. Reddy's Laboratories
2.9487 of 5 stars
$13.23
+4.3%
$17.00
+28.5%
-6.7%$11.04B$311.31B21.0624,800Gap Up
ASND
Ascendis Pharma A/S
3.0809 of 5 stars
$168.84
+10.4%
$202.36
+19.9%
+15.8%$10.25B$363.64M-23.781,017News Coverage
Positive News
Gap Up
High Trading Volume
SRPT
Sarepta Therapeutics
4.5729 of 5 stars
$101.35
+4.3%
$170.41
+68.1%
-40.2%$9.83B$1.90B81.081,314
PCVX
Vaxcyte
2.3362 of 5 stars
$75.23
+1.2%
$147.50
+96.1%
+9.8%$9.69BN/A-16.35160Positive News
Remove Ads

Related Companies and Tools


This page (NASDAQ:CYTK) was last updated on 3/25/2025 by MarketBeat.com Staff
From Our Partners